GeoVax Labs Inc. (NASDAQ:GOVX) Sees Significant Drop in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant decrease in short interest in February. As of February 27th, there was short interest totaling 210,698 shares, a decrease of 22.7% from the February 12th total of 272,648 shares. Currently, 11.6% of the company’s shares are short sold. Based on an average trading volume of 160,711 shares, the days-to-cover ratio is currently 1.3 days. Based on an average trading volume of 160,711 shares, the days-to-cover ratio is currently 1.3 days. Currently, 11.6% of the company’s shares are short sold.

Institutional Investors Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sabby Management LLC purchased a new stake in GeoVax Labs in the 3rd quarter worth approximately $313,000. Renaissance Technologies LLC purchased a new position in GeoVax Labs during the fourth quarter valued at approximately $104,000. Jane Street Group LLC bought a new position in shares of GeoVax Labs in the fourth quarter worth approximately $99,000. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs in the third quarter worth $253,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs during the 4th quarter valued at $31,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GOVX has been the subject of a number of research analyst reports. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $187.50.

GeoVax Labs Stock Performance

Shares of GOVX stock traded down $0.14 during mid-day trading on Friday, reaching $1.72. 28,770 shares of the company’s stock traded hands, compared to its average volume of 140,565. The firm has a 50 day moving average price of $2.56 and a two-hundred day moving average price of $9.12. The firm has a market capitalization of $3.13 million, a PE ratio of -0.05 and a beta of 3.81. GeoVax Labs has a 12 month low of $1.26 and a 12 month high of $40.50.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.